胶质瘤中的免疫抑制机制综述
该综述回顾了胶质瘤局部及全身免疫抑制的临床前与临床证据,归纳了肿瘤诱导T细胞和NK细胞功能障碍、调节性T细胞与髓源性抑制细胞扩增、M2型巨噬细胞转化、免疫抑制因子上调、微环境缺氧及治疗相关医源性免疫抑制等机制。胶质瘤形成深刻的免疫抑制环境,未来研究应针对这些机制开发具有生存获益的治疗方案。
要点
- 胶质瘤通过多种机制局部和全身抑制免疫,限制免疫治疗疗效。
- 机制包括T/NK细胞功能障碍、Treg与MDSC扩增、M2巨噬细胞转化等。
- 未来需靶向免疫抑制机制以改善患者生存。
核心结论
- 胶质瘤在肿瘤局部和全身均形成深刻的免疫抑制环境。
- 未来研究应针对这些免疫抑制机制开发具有生存获益的治疗方案。
研究设计与样本
- 综述回顾了胶质瘤疾病过程中免疫抑制的临床前和临床证据。
主要发现
- 肿瘤诱导T细胞和NK细胞功能障碍。
- 调节性T细胞和髓源性抑制细胞扩增。
- 胶质瘤相关巨噬细胞/小胶质细胞发生M2表型转化。
- 免疫抑制性胶质瘤细胞表面因子和细胞因子上调。
- 肿瘤微环境缺氧及免疫抑制治疗的医源性后遗症参与免疫抑制。
临床怎么用
- 临床应认识胶质瘤局部和全身免疫抑制对治疗疗效的限制。
- 未来治疗策略需针对上述免疫抑制机制以争取生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The overall survival in patients with gliomas has not significantly increased in the modern era, despite advances such as immunotherapy. This is in part due to their notorious ability to suppress local and systemic immune responses, severely restricting treatment efficacy. METHODS: We have reviewed the preclinical and clinical evidence for immunosuppression seen throughout the disease process in gliomas. This review aims to discuss the various ways that brain tumors, and gliomas in particular, co-opt the body's immune system to evade detection and ensure tumor survival and proliferation. RESULTS: A multitude of mechanisms are discussed by which neoplastic cells evade detection and destruction by the immune system. These include tumor-induced T-cell and NK cell dysfunction, regulatory T-cell and myeloid-derived suppressor cell expansion, M2 phenotypic transformation in glioma-associated macrophages/microglia, upregulation of immunosuppressive glioma cell surface factors and cytokines, tumor microenvironment hypoxia, and iatrogenic sequelae of immunosuppressive treatments. CONCLUSIONS: Gliomas create a profoundly immunosuppressive environment, both locally within the tumor and systemically. Future research should aim to address these immunosuppressive mechanisms in the effort to generate treatment options with meaningful survival benefits for this patient population.
引用
- Grabowski MM, Sankey EW, Ryan KJ, et al. Immune suppression in gliomas. J Neurooncol. 2020. PMID: 32542437. doi:10.1007/s11060-020-03483-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。